PubRank

Adil Al-Nahhas

Author PubWeight™ 83.53‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007 2.35
2 Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008 2.27
3 Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 2007 1.72
4 Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res 2011 1.64
5 Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun 2007 1.46
6 Role of 99mTc-sestamibi SPECT in accurate selection of primary hyperparathyroid patients for minimally invasive radio-guided surgery. Eur J Nucl Med Mol Imaging 2006 1.43
7 Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005 1.42
8 EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012 1.28
9 Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol 2010 1.20
10 Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl Med Commun 2007 1.19
11 Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med 2012 1.17
12 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 2011 1.14
13 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol 2007 1.09
14 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009 1.09
15 What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging 2007 1.06
16 Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007 1.05
17 Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres. Nucl Med Commun 2007 1.03
18 [18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res 2011 1.00
19 Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients: are there sources of benign secretion? A speculative short review. Nucl Med Commun 2010 0.99
20 Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res 2009 0.98
21 68Ga DOTATATE PET/CT uptake in spinal lesions and MRI correlation on a patient with neuroendocrine tumor: potential pitfalls. Clin Nucl Med 2013 0.97
22 Anatomical and functional localization of ectopic parathyroid adenomas: 6-year institutional experience. Nucl Med Commun 2011 0.97
23 Highlights of the EANM Congress 2011: Birmingham, UK. Eur J Nucl Med Mol Imaging 2012 0.96
24 Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med 2007 0.96
25 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 2007 0.96
26 Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med 2013 0.95
27 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med 2013 0.95
28 Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET. Nucl Med Commun 2007 0.94
29 Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 2007 0.94
30 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study. Eur J Radiol 2010 0.92
31 PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging 2008 0.91
32 Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies. Phys Med Biol 2010 0.89
33 [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res 2009 0.89
34 Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Mol Imaging Biol 2012 0.89
35 Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. Biomed Pharmacother 2007 0.88
36 Noninvasive and invasive staging of ovarian cancer: review of the literature. Clin Nucl Med 2011 0.87
37 Molecular imaging of Takayasu's arteritis and other large-vessel vasculitis with 18F-FDG PET. Nucl Med Commun 2006 0.87
38 Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers. Nucl Med Commun 2011 0.86
39 Selective internal radiation therapy with Yttrium-90 for unresectable liver tumours. Rev Recent Clin Trials 2007 0.85
40 Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 2010 0.85
41 Synthesis and quality control of 68Ga citrate for routine clinical PET. Nucl Med Commun 2009 0.85
42 Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography. Nucl Med Commun 2011 0.85
43 Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Nucl Med Rev Cent East Eur 2006 0.85
44 Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. Nucl Med Commun 2007 0.84
45 FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol 2010 0.84
46 Can gallium-68 compounds partly replace (18)F-FDG in PET molecular imaging? Hell J Nucl Med 2009 0.83
47 Feasibility and long-term results of focused radioguided parathyroidectomy using a "low" 37 MBq (1 mCi) 99mTc-sestamibi protocol. Int Semin Surg Oncol 2006 0.83
48 Additional value of FDG-PET/CT in management of "solitary" liver metastases: preliminary results of a prospective multicenter study. Mol Imaging Biol 2009 0.83
49 Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteers. J Nucl Med 2014 0.83
50 Occult squamous cell carcinoma of the uvula detected by F-18 FDG PET/CT in a case of carcinoma of unknown primary in the head and neck. Clin Nucl Med 2010 0.83
51 Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer. Nucl Med Commun 2011 0.83
52 The impact of superficial injections of radiocolloids and dynamic lymphoscintigraphy on sentinel node identification in oral cavity cancer: a same-day protocol. Nucl Med Commun 2008 0.83
53 F-18 FDG PET/CT in rectal carcinoma: where are we now? Clin Nucl Med 2011 0.82
54 Tumor marker-guided PET in breast cancer patients-a recipe for a perfect wedding: a systematic literature review and meta-analysis. Clin Nucl Med 2012 0.82
55 The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia. Expert Rev Neurother 2011 0.82
56 Extended staging of oesophageal cancer using FDG-PET - a critical appraisal. Eur J Radiol 2010 0.81
57 Embolization of hepatic arterial branches to simplify hepatic blood flow before yttrium 90 radioembolization: a useful technique in the presence of challenging anatomy. Cardiovasc Intervent Radiol 2010 0.81
58 Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer. Nucl Med Commun 2014 0.81
59 Can we avoid inadvertent parathyroidectomy during thyroid surgery? In Vivo 2009 0.80
60 Small animal PET in oncology: the road from bench to bedside. Cancer Biother Radiopharm 2009 0.80
61 Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy. Nucl Med Rev Cent East Eur 2007 0.80
62 Deep-seated resistance in relapsed paratyphoid fever. Clin Infect Dis 2006 0.80
63 Positron emission tomography in schizophrenia: a new perspective. J Nucl Med 2010 0.80
64 Clinical significance of myocardial perfusion abnormalities in patients with varying degree of coronary artery stenosis. Nucl Med Commun 2008 0.80
65 Detection of bilateral, multifocal breast cancer and assessment of tumour response to neoadjuvant chemotherapy by Tc-99m sestamibi imaging - a case report. Nucl Med Rev Cent East Eur 2008 0.80
66 Indeterminate pulmonary nodules on CT images in breast cancer patient: the additional value of 18F-FDG PET/CT. J Med Imaging Radiat Oncol 2012 0.80
67 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun 2012 0.79
68 The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging 2006 0.79
69 Distant metastases of differentiated thyroid cancer: diagnosis, treatment and outcome. Nucl Med Rev Cent East Eur 2007 0.79
70 Labelling of granulocytes by phagocytic engulfment with 64Cu-labelled chitosan-coated magnetic nanoparticles. Mol Imaging Biol 2012 0.78
71 Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab. Clin Cancer Res 2010 0.78
72 Factors affecting the measurement of left ventricular ejection fraction in myocardial perfusion imaging. Nucl Med Commun 2009 0.78
73 Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging. Nucl Med Commun 2014 0.78
74 F-18 FDG uptake in bilateral pulmonary artery leiomyosarcomata, one mimicking a pulmonary embolus. Clin Nucl Med 2005 0.78
75 Minimally invasive radio-guided parathyroidectomy: long-term results with the 'low 99mTc-sestamibi protocol'. Nucl Med Commun 2006 0.78
76 Novel PET biomarkers for breast cancer imaging. Nucl Med Commun 2011 0.78
77 Diagnosis of infected total knee arthroplasty with anti-granulocyte scintigraphy: the importance of a dual-time acquisition protocol. Nucl Med Commun 2008 0.78
78 Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy. Phys Med Biol 2012 0.78
79 What impact can fluorine-18 fluorodeoxyglucose PET/computed tomography have on HIV/AIDS and tuberculosis pandemic? Nucl Med Commun 2009 0.78
80 Diagnostic and prognostic value of gated myocardial perfusion single-photon emission computed tomography in low-risk patients with left bundle-branch block. Nucl Med Commun 2012 0.77
81 (99m)Tc-MAG3 diuretic renography in diagnosis of obstructive nephropathy in adults: a comparison between F-15 and a new procedure F+10(sp) in seated position. Clin Nucl Med 2013 0.77
82 The evolving role of PET/CT in breast cancer. Nucl Med Commun 2010 0.77
83 Clinical significance of metabolic superscan in patients with hyperthyroidism. Nucl Med Rev Cent East Eur 2007 0.77
84 Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma. Nucl Med Rev Cent East Eur 2005 0.77
85 Skin eruptions following treatment with Iodine-131 for hyperthyroidism: a rare and un-reported early/intermediate side effect. Nucl Med Rev Cent East Eur 2005 0.77
86 FDG PET/CT in ovarian cancer: what about treatment response and prognosis? Clin Nucl Med 2012 0.77
87 Reliability of white blood cell scan in the follow-up of osteomyelitis. Biomed Pharmacother 2007 0.76
88 F-18 FDG PET in the diagnosis and monitoring of salmonella vertebral osteomyelitis: a comparison with MRI. Clin Nucl Med 2006 0.75
89 Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl Med Commun 2013 0.75
90 Iodine-123 uptake in vertebral haemangiomas in a patient with papillary thyroid carcinoma. Nucl Med Rev Cent East Eur 2008 0.75
91 FDG-PET imaging in Pneumocystis carinii pneumonia. Clin Nucl Med 2005 0.75
92 68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients. Nucl Med Commun 2008 0.75
93 Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Hell J Nucl Med 2015 0.75
94 Colorectal cancer: translation of biological pathways into molecular imaging. Nucl Med Commun 2012 0.75
95 Insights into schizophrenia using positron emission tomography: building the evidence and refining the focus. Br J Psychiatry 2010 0.75
96 Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours. Neuroendocrinology 2015 0.75
97 Acrometastasis to the foot: an unusual presentation of transitional cell carcinoma of the bladder. Nucl Med Rev Cent East Eur 2007 0.75
98 Positron-emission tomography in gynaecologic malignancies. Arch Gynecol Obstet 2009 0.75
99 The Response Evaluation Criteria in Solid Tumors: until when? Nucl Med Commun 2009 0.75
100 Treatment of local and regional recurrences of differentiated thyroid cancer by radio-guided surgery with iodine-131. Nucl Med Rev Cent East Eur 2006 0.75
101 The labeled-leukocyte scan in the study of abdominal abscesses. Mol Imaging Biol 2010 0.75
102 Pulmonary emboli and extramedullary haematopoiesis in beta-thalassaemia intermedia. Nucl Med Rev Cent East Eur 2008 0.75
103 Utility of left lateral supine position for myocardial perfusion single-photon emission computed tomography compared with other methods of correcting inferior wall attenuation. Nucl Med Commun 2015 0.75
104 White blood cell scan in the follow-up of infectious diseases: is the withdrawal of antibiotic therapy necessary? Nucl Med Commun 2007 0.75
105 Superior vena cava obstruction as suggested by extrapulmonary uptake on lung scintigraphy. Clin Nucl Med 2006 0.75
106 Antigranulocyte scintigraphy in infected hip prosthesis: the diagnostic importance of delayed 20-24-h imaging and semiquantitative analysis. Nucl Med Commun 2008 0.75
107 Reliability and reproducibility of N-[11C]methyl-choline and L-(S-methyl-[11C])methionine solid-phase synthesis: a useful and suitable method in clinical practice. Nucl Med Commun 2008 0.75
108 The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study. Nucl Med Rev Cent East Eur 2007 0.75
109 Role of small animal PET in stimulating the development of new radiopharmaceuticals in oncology. Nucl Med Commun 2007 0.75
110 Changes in the expression of somatostatin receptor imaging following Y-90 lanreotide therapy for carcinoid tumor: a flare response? Clin Nucl Med 2005 0.75
111 The new cover. Nucl Med Commun 2010 0.75
112 Preoperative diagnosis of orbital cavernous hemangioma: a 99mTc-RBC SPECT study. Clin Nucl Med 2012 0.75
113 Combination of physical exercise and adenosine improves accuracy of automatic calculation of stress LVEF in gated SPECT using QGS software. Nucl Med Rev Cent East Eur 2005 0.75
114 A rare combination of cardiopulmonary anomalies demonstrated on ventilation-perfusion scan. Nucl Med Rev Cent East Eur 2008 0.75
115 18F-fluorodeoxyglucose-positron emission tomography imaging in idiopathic inflammatory myositis. Nucl Med Commun 2008 0.75
116 Renal scintigraphy predicts global cardiovascular risk in hypertensive subjects with normal serum creatinine levels. Blood Press 2011 0.75
117 The role of 18F-FDG PET in oncology: clinical and resource implications. Nucl Med Rev Cent East Eur 2006 0.75
118 Tc-99m MDP and Tc-99m MIBI in the assessment of spondyloarthritis presenting as bone metastasis before treatment with infliximab. Clin Nucl Med 2002 0.75
119 Radioguided surgery and systemic radionuclide therapy of neuroendocrine tumours. In Vivo 2010 0.75
120 Is there an ideal algorithm in preoperative localisation of primary hyperparathyroidism? Nucl Med Rev Cent East Eur 2006 0.75
121 Significance of posture and workload in exercise renography. Nucl Med Rev Cent East Eur 2006 0.75
122 Clinical PET in oncology: not only FDG. Nucl Med Commun 2006 0.75
123 Correlative imaging with (18)F-FDG PET/CT and MRI in paraneoplastic limbic encephalitis. Clin Nucl Med 2013 0.75
124 The value of combined assessment of vertebral fractures with 99mTc MDP scintigraphy and MRI in selecting and planning percutaneous vertebroplasty. Nucl Med Commun 2014 0.75
125 Yttrium-90 radiation synovectomy revisited. Nucl Med Commun 2016 0.75
126 Can PET/CT imaging advance our understanding of the neurobiology of schizophrenia? Nucl Med Commun 2010 0.75
127 The value of simultaneous co-registration of 99mTc- MDP and 131Iodine in metastatic differentiated thyroid carcinoma. Nucl Med Rev Cent East Eur 2007 0.75
128 FDG-PET detection of primary bone marrow large B-cell lymphoma in a patient with hairy cell leukemia. Nucl Med Rev Cent East Eur 2007 0.75
129 Current practice in pancreatic imaging: the role of nuclear medicine. Nucl Med Commun 2006 0.75